Navigation Links
New Cancer-Fighting Strategy Focuses On Signaling Molecules
Date:2/24/2010

Cancer researchers studying the immune system have identified a previously unrecognized set of targets and biomarkers to battle solid tumors.

(Vocus) February 24, 2010 -- Cancer researchers studying the immune system have identified a previously unrecognized set of targets and biomarkers to battle solid tumors.

The findings center on discovery of signaling molecules that are major players in a biochemical mechanism linking certain actions of B cells to solid tumor growth. The most notable implication of the study is that a drug in use for more than decade to treat non-Hodgkin’s lymphoma, which is a cancer of the B cells, might be effective against other solid tumors, says lead author Lisa Coussens, PhD, of the UCSF Helen Diller Family Comprehensive Cancer Center.

“This is paradigm shifting,” emphasizes Coussens, who is a pioneer in studying the role of molecular regulation in cellular inflammation that is linked to development of cancer. “The discoveries open up our thinking to many new signaling molecules as potential therapeutic targets.’’

The research is published online and in print by the scientific journal “Cancer Cell” (vol.17, issue 2, http://www.cell.com/cancer-cell/current).

“These are very significant findings because they suggest that Rituxan, a drug that we already are familiar with, could have very broad clinical implications in the treatment of some solid tumors,’’ says Coussens, who also is a professor in the UCSF Department of Pathology and co-director of the Mouse Pathology Core and Program in Cancer, Immunity and Microenvironment.

The researchers found that a class of antibodies known as immunoglobulin G and the receptors to which they bind play a key role in the link between B cells and solid tumor growth. Called FcRgamma, these receptors are found on cells of the innate immune system (including mast cells, macrophages, and dendritic cells). The activation of FcRgamma plays a part in recruiting circulating immune cells to neoplastic (abnormal) tissue, which in turn enhances development of new blood vessels to feed nutrients to growing tumors and to advance progression to malignant cancer.

Most tumors are rife with activated immune cells, says Coussens, but their role in the development of cancer has been largely overlooked.

The findings may lead to more successful treatment of certain solid tumors by combining chemotherapy with drugs that can thwart cancer-promoting activities of the immune system, according to Coussens. For instance, the drug Rituxan has relatively few side effects, she adds.

As a result of the molecular discovery, Coussens is collaborating with pharmaceutical industry experts to explore new therapeutic strategies. Preclinical testing of the combination approach is underway involving therapies similar to Rituxan and chemotherapy, and initial results “look promising,’’ says Coussens.

At UCSF, the Coussens lab focuses on the role of inflammatory cells and leukocyte proteases as critical regulators of skin, lung and breast cancer development. During the early development of cancer, many physiological processes occur in the vicinity of young tumor cells that are similar to processes that occur during embryonic development and to healing of wounds in adult tissue.

By studying mouse models of skin, lung and breast cancer development, the Coussens lab is identifying important molecules involved in regulating tumor-associated inflammation, angiogenesis, and cancer development. Identification of these important regulatory mechanisms reveals drug-targets that can then be used to design novel therapeutic strategies for treating cancer development in humans.

Biochemical and cellular studies during the past decade have shown that inflammation can promote the development of cancer. In addition, certain chronic inflammatory conditions, such as Crohn’s disease, pancreatitis, prostatitis, asbestosis and Barrett’s esophagus, are associated with an elevated cancer risk.

Discoveries over the last decade have made clear that “Chronic inflammation in the context of tumor development is associated with a poor prognosis,’’ says Coussens.
Other study authors include Pauline Andreu, PhD; Magnus Johansson, PhD; Nesrine I. Affara, PhD, and David DeNardo, PhD, postdoctoral scholars in the Coussens laboratory and in the Department of Pathology.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.

###

Read the full story at http://www.prweb.com/releases/ucsf-cancer_research/signal-molecules/prweb3650874.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Gap Inc., The Leukemia & Lymphoma Society Encourage Shoppers to Support Cancer-Fighting Programs
2. Scientists produce nanoscale droplets with cancer-fighting implications
3. Video: Trinity Mother Frances and Texas Oncology-Tyler Among the First in U.S. to Boast New Cancer-Fighting Technology
4. Enzyme may hold key to improved targeting of cancer-fighting drugs
5. Stabilizing cancer-fighting p53 can also shield a metastasis-promoter
6. Skin flaps deliver cancer-fighting therapy, ASPS study reveals
7. New strategy produces promising advance in cancer vaccines
8. Data Strategy Announces SurePath Services Offering for EMC Avamar
9. Keenan Chief Strategy Officer Selected to Join Editorial Board of Payers & Providers
10. SOKO Fitness & Spa Group Broadens Geographic Expansion Strategy
11. Governor Rendell Proposes Budget With No Tax Increase, More Money for Public Schools, Strategy for Jobs, Plan to Address Future Deficits
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Cancer-Fighting Strategy Focuses On Signaling Molecules
(Date:2/9/2016)... ... ... Establishment Labs, a global breast implant and medical technology company, is pleased ... , “We are honored to welcome David to our Board of Directors. ... Quiros, CEO of Establishment Labs. "David’s knowledge and experience will be invaluable to our ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... service to expand access to affordable hearing aids , increase industry transparency, ... individuals in the United States. , “For the average consumer, the hearing aid ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... sealing company , is proud to announce that many of their franchises have ... customer service. The hard surface restoration franchises received customer recognition through positive reviews ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Federal Laboratory ... federallabs.org . The site houses a wealth of federal resources that businesses can ... process called technology transfer (T2). As a network of over 300 federal laboratories, ...
(Date:2/8/2016)... Los Angeles, CA (PRWEB) , ... February 08, 2016 , ... A man who has ... CEO of Freedom Laser Therapy , was determined to find solutions to his problems ... story of Inventors Digest is ready to introduce his breakthrough inventions to the ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... , February 9, 2016 ... QIA) gab heute den Abschluss eines Kooperationsvertrags ... Förderung umfassender Lösungen in den Bereichen Next-Generation-Sequencing ... QGEN ; Frankfurt Prime Standard: QIA) ... 10x Genomics für die Entwicklung und Förderung ...
(Date:2/9/2016)... 9, 2016 Mast Therapeutics, Inc. (NYSE ... sickle cell disease and heart failure, today announced that it ... purchase common stock in an underwritten public offering.  The offering ... be no assurance as to whether or when the offering ... terms of the offering.   --> ...
(Date:2/9/2016)... 9, 2016 Hearing protection devices refer to ... transmitted to the inner ear. Hearing protection devices include ... devices are recommended for users exposed to noise levels ... to HPD that are inserted in the ear canal ... to provide more natural sound perception with the help ...
Breaking Medicine Technology: